Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
INFA Group was an Italian active pharmaceutical ingredient and fine chemicals company focused on generic APIs, custom synthesis, and pharmaceutical manufacturing services. The business operated as a fully integrated organization with FDA-inspected manufacturing assets in Italy and Spain and a commercial footprint spanning Europe and the United States. Its affiliated companies included Labochim, Sifavitor, and Derivados Quimicos, and it offered services across API supply as well as CMO/CRO support for pharmaceutical and fine chemical customers. INFA Group was acquired by Olon in 2016, and its capabilities were integrated into the broader Olon API and CDMO network. As a result, INFA Group is best understood today as a historical acquired API platform rather than an independent operating biotech drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on INFA Group.